POEMS Syndrome
POEMS Syndrome
Overview
- POEMS syndrome is a rare paraneoplastic disorder driven by an underlying clonal plasma cell disorder. The acronym: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein (usually IgA or IgG with λ light chains), Skin changes.
- VEGF (vascular endothelial growth factor) is characteristically elevated and correlates with disease activity (typically plasma levels >200 pg/mL); normalization tracks with response.
- Associated with Castleman disease and with osteosclerotic bone lesions (contrast with the lytic lesions of multiple myeloma).
Illustrative Case
- A 57-year-old baseball coach presented with bilateral calf cramping and rapid weakness. Workup revealed a sclerotic lesion in the right iliac bone plus multiple lytic pelvic and femoral lesions; CT-guided biopsy showed λ-restricted plasmacytoma. Marrow was normocellular without increased plasma cells or amyloid, and renal function/calcium were normal.
- Small M-spike IgA λ 0.4 g/dL, free λ 75.8 mg/L (ratio 0.21), VEGF 500 pg/mL (normal up to 100), low free testosterone. Treated with radiation to the dominant sclerotic lesion plus lenalidomide/dexamethasone (VEGF normalized, performance status improved though sFLC ratio remained abnormal), then autologous HSCT with melphalan, in continued CR.
Diagnostic Criteria
POEMS syndrome: diagnostic criteria
| Category | Criteria |
|---|---|
| Mandatory(both required) |
|
| Major(≥1 required) |
|
| Minor(≥1 required) |
|
Frequency of Clinical Findings
POEMS: frequency of clinical findings
| Frequency | Finding |
|---|---|
| 100% | Polyneuropathy (chronic, progressive, demyelinating; not autonomic; motor > sensory) |
| 100% | Monoclonal plasma cell disorder (usually λ) |
| Most | Increased CSF protein (>50 mg/dL; common, usually without pleocytosis, but not universal or required, and normal CSF does not exclude POEMS) |
| 97% | Osteosclerotic bone lesions |
| 68% | Skin changes |
| 67% | Endocrinopathy |
| 50% | Organomegaly (hepatosplenomegaly, lymphadenopathy) |
| 37% | Weight loss (>10 pounds) |
| 31% | Fatigue |
| 29% | Papilledema |
| 29% | Edema, ascites, pleural effusion |
| 15% | Castleman disease |
| 5% | Clubbing |
Treatment
- Limited disease (1 to 3 sclerotic lesions, no marrow involvement): radiation therapy 40 to 50 Gy to the involved field. This can be curative for truly localized disease.
- Disseminated disease (bone lesions beyond a limited 1 to 3, marrow involvement, or progression despite radiation): systemic therapy, then autologous stem cell transplant (ASCT) if eligible.
- Active systemic regimens: lenalidomide, lenalidomide/dexamethasone, bortezomib/dexamethasone, cyclophosphamide/dexamethasone, pomalidomide/dexamethasone.
- Response monitoring: VEGF is a useful marker of disease activity and treatment response.
High-Yield Pearls
- The monoclonal protein is almost always λ-restricted, and bone lesions are characteristically osteosclerotic, but mixed sclerotic-lytic and purely lytic lesions also occur (contrast the typically lytic lesions of MM).
- Diagnosis requires both mandatory criteria (polyneuropathy that is typically demyelinating, though axonal features are common and formal CIDP criteria are not required, plus a monoclonal plasma cell disorder) plus at least one major and one minor criterion.
- Elevated VEGF and Castleman disease are major criteria; isolated thyroid dysfunction or diabetes does not count toward endocrinopathy.
- Localized osteosclerotic disease is treated with radiation; widespread disease is treated with systemic therapy and ASCT.
Veli Bakalov MD, Board Review Notes 2026